ArticleEndocrine2025
Decisive role of surgery on improving overall survival outcomes of primary thyroid sarcoma: the first long-term cohort study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary Thyroid Sarcoma (PTS) accounts for 1-2% of thyroid malignancies with limited survival data available. And it might be misidentified as the spindle cell subtype of anaplastic thyroid carcinoma (ATC) due to overlapping pathological features, which poses a significant diagnostic challenge.
methodsA total of 42 PTS patients from 2000 to 2018 were screened from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival curve, Cox proportional hazard regression were applied.
resultsMost patients with PTS are middle-aged to old, predominantly white, and slightly more female. The 5-year overall survival (OS) and 5-year disease specific survival (DSS) were 28.3% and 60.5%, respectively. Older age (>55 vs <=40, HR = 6.45, 95% CI 2.16-19.24, P < 0.001), undifferentiated pathological grade (vs moderately differentiated, HR = 17.02, 95% CI 1.74-166.89, P = 0.015), higher SEER stage (e.g., distant vs localized, HR = 7.76, 95% CI 2.12-8.84, P = 0.002), distant metastasis (M1 vs M0, HR = 2.93, 95% CI 1.09-7.91, P = 0.034) and no surgery performed (lobectomy vs no surgery, HR = 0.11, 95% CI 0.03-0.42, P = 0.001; total thyroidectomy vs no surgery, HR = 0.05, 95% CI 0.01-0.20, P < 0.001) were identified as independent prognostic factors, in which, surgery is the only factor that improves survival outcomes of PTS patients.
conclusionThe current study outlined the features of PTS patients in demographic and clinical characteristics, survival outcomes, prognostic factors, general layout of cause of deaths and the desicive role of surgery in improving its survival benefits.
Indexed as
Identifiers
40473895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.